ABVC BioPharma has announced significant operational enhancements at its BioKey subsidiary's 28,176-square-foot pharmaceutical development and manufacturing facility in Silicon Valley. The Fremont, California location serves as a central component of ABVC's global chemistry, manufacturing, and controls strategy and U.S.-Asia development approach, featuring formulation development laboratories, analytical laboratories, quality-aligned production areas, and warehousing capabilities.
The facility operates as a single-location, multi-product development center supporting pharmaceutical formulations, botanical and plant-based products, controlled-release and specialized solid-oral dosage forms, and functional food and nutraceutical products. All activities from formulation through pilot-scale preparation are performed entirely within the United States, providing a fully domestic development pathway that reduces cross-border complexities and enhances supply-chain resilience. This integrated approach enables simultaneous support of multiple therapeutic and nutraceutical projects under coordinated oversight.
BioKey's operational capabilities include formulation development for pharmaceuticals and functional food products, process development and pilot-scale preparation, analytical testing, stability studies, quality documentation, and technical and regulatory support for U.S. and international submissions. The facility also provides cross-functional support for technology-transfer and long-term development programs, creating a comprehensive development ecosystem within a single integrated location.
The expansion outlook through 2030 represents a significant economic development opportunity for the Silicon Valley region. ABVC anticipates that BioKey's expanded activities, operational growth, and partner-supported programs will enable and support up to 1,000 jobs across formulation, analytical development, quality operations, regulatory support, documentation, data management, and supply-chain coordination by the end of the decade.
The Fremont facility features over 12,054 square feet of expansion-ready space that can accommodate additional analytical capacity, expanded development and production workflows, technology-transfer and documentation centers, and functional food and clinical material preparation zones. This expansion capacity supports the company's medium-term development plan targeting expanded U.S.-Asia CMC execution and increased participation in global pharmaceutical and functional food innovation.
Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that BioKey serves as an essential pillar of ABVC's global development strategy. The Silicon Valley facility provides a fully U.S.-based platform capable of supporting multiple pharmaceutical, botanical, and functional food programs from early formulation through pilot preparation, positioning the company for sustained growth in the evolving healthcare and nutrition sectors. More detailed information about the company is available through the Securities and Exchange Commission's website at https://www.sec.gov.
